Hypothalamic BDNF Gene Therapy for Sustained Obesity Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmacological and surgical treatments for obesity are either ineffective or come with severe adverse effects, and there is a need for safer and more effective approaches to treat metabolic disorders such as obesity.
Innovation Solution
Development of BDNF gene therapy expression constructs and vectors, including a promoter sequence operatively linked to a nucleic acid sequence encoding brain-derived neurotrophic factor (BDNF), which are administered to increase BDNF levels in the subject, utilizing a vector like adeno-associated virus (AAV) to target the hypothalamus for appetite regulation and weight management.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If current pharmacological treatments (appetite suppressors, nutrient-absorption inhibitors) are used, then weight loss may be achieved, but severe adverse effects occur
Solution Approach 1:
The patent replaces pharmacological chemical interventions with a gene therapy approach using viral vectors to deliver BDNF cDNA. This substitution transitions from direct drug administration affecting multiple systems to a targeted genetic modification that produces the therapeutic protein endogenously, thereby achieving weight loss while minimizing severe adverse effects associated with conventional medications.
Solution Approach 2:
The patent introduces BDNF as an intermediary substance that mediates the therapeutic effect. The viral vector delivers BDNF cDNA, which then produces BDNF protein that acts on hypothalamic circuits to regulate appetite and energy expenditure. This intermediary approach avoids direct use of harsh pharmacological agents while achieving the desired weight loss effect.
2Quantity of substance
If bariatric surgery is performed, then significant weight loss is achieved, but significant morbidity occurs
Solution Approach 1:
The patent replaces the mechanical/surgical intervention of bariatric surgery with a molecular biology-based gene therapy approach. Instead of physically altering the gastrointestinal tract, the therapy uses viral vectors to modify gene expression in hypothalamic neurons, achieving weight loss through physiological regulation rather than structural modification, thereby avoiding surgical morbidity.
Solution Approach 2:
The patent changes the fundamental parameter of treatment from macroscopic surgical intervention to microscopic molecular intervention. By altering the expression level of BDNF protein through genetic modification, the therapy achieves weight loss by changing the biochemical parameters of appetite and energy expenditure regulation, avoiding the physical trauma and complications of surgery.
3Quantity of substance
If pharmacological therapies (semaglutide, tirzepatide) are administered, then weight loss is achieved, but patient adherence is required and inflammation occurs at injection sites
Solution Approach 1:
The patent implements a self-service therapeutic system where the patient's own cells are modified to produce the therapeutic protein. The viral vector delivers BDNF cDNA to hypothalamic neurons, which then continuously produce BDNF protein endogenously. This eliminates the need for ongoing patient adherence to injection regimens, as the therapeutic effect is sustained by the modified cells themselves.
Solution Approach 2:
The patent performs preliminary action by permanently modifying the patient's hypothalamic neurons through gene delivery before the treatment period begins. The viral vector establishes persistent BDNF expression in the target cells, creating a long-lasting therapeutic effect that eliminates the need for repeated administrations and ongoing patient compliance required by conventional pharmacological therapies.
4Quantity of substance
If pharmacological therapies are administered, then weight loss is achieved, but inflammation occurs at injection sites
Solution Approach 1:
The patent replaces repeated parenteral injections with a single gene delivery intervention. The viral vector is administered once to establish persistent BDNF expression, eliminating the need for ongoing injections that cause localized inflammation. This substitution transitions from repeated invasive chemical delivery to a single molecular intervention with sustained effect.
Data Source
AI summary
This disclosure provides BDNF expression constructs and vectors comprising such constructs for treating metabolic disorders, including, but not limited to, obesity. The disclosed BDNF gene therapy is more effective than existing BDNF-based gene therapy constructs.